Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

The proposed financing would support Phase 3 readiness and a new SPY072 late-stage development program for hidradenitis suppurativa.

Rhea-AI Summary

Spyre Therapeutics (SYRE) has commenced a proposed underwritten public offering of common stock to fund continued development of its programs. The company expects to grant underwriters a 30-day option to purchase an additional 15% of the shares offered on the same terms. Completion is subject to market and other conditions.

Spyre intends to use net proceeds to advance Gastroenterology, Rheumatology and Dermatology programs through preclinical studies, clinical trials, manufacturing and Phase 3 readiness. Proceeds would also support a new program to advance SPY072 into late-stage development for hidradenitis suppurativa. Jefferies, TD Cowen, Leerink Partners and Stifel are joint book-running managers; LifeSci Capital is passive bookrunner.

3 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed common stock offering would raise funding for Spyre’s development programs.
• Minor point. Forward-looking: it has not happened yet and may not happen.Planned proceeds would fund preclinical studies, clinical trials, manufacturing and Phase 3 readiness across three therapeutic areas.
• Minor point. Forward-looking: it has not happened yet and may not happen.Planned proceeds would support a new SPY072 program targeting late-stage development for hidradenitis suppurativa.

Negative

• Moderate point. Forward-looking: it has not happened yet and may not happen.Proposed issuance of common stock would dilute existing shareholders.
• Minor point. Forward-looking: it has not happened yet and may not happen.Expected 30-day underwriter option for an additional 15% of offered shares would add dilution if exercised.
• Minor pointOffering completion remains subject to market and other conditions.

News Explained

Spyre has commenced a still-proposed common-stock offering, but disclosed no share count or price; if completed, issuing shares would reduce existing holders’ percentage ownership, and final terms are due in a prospectus supplement.

Argus 15 min delay 1 alert

-4.29% vs previous close $88.74 last price 0.6x rel. volume Open Argus

Details

Market move: SYRE -4.29% vs previous close. Proposed public offering

$87.95 – $95.01 Day Range

$7.82B Market Cap

On Oct 5, the day this news came out, the latest delayed price for SYRE is 4.29% below the previous close. The latest delayed price is $88.74.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Underwriter option period: 30 days Additional shares option: 15% of shares offered

Underwriter option period

30 days

Expected option period for the proposed offering

Additional shares option

15% of shares offered

Expected underwriter option under the same terms and conditions

Key Terms

underwritten public offering, phase 3, hidradenitis suppurativa, form s-3, +1 more

5 terms

underwritten public offering financial

"commenced an underwritten public offering of its common stock"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

phase 3 medical

"manufacturing, and Phase 3 readiness"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

hidradenitis suppurativa medical

"late-stage development for hidradenitis suppurativa"

A chronic skin disease marked by recurring, painful lumps and tunnels under the skin that often leak and leave scars; it behaves like a slow-burning, recurring infection in areas with many sweat glands. For investors, it matters because the condition has few consistently effective treatments and causes long-term healthcare use, making successful new drugs, devices, or diagnostics potentially high-value opportunities while also carrying clinical-trial, regulatory and reimbursement risks.

form s-3 regulatory

"registration statement on Form S-3"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"by means of a prospectus supplement and accompanying prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase an additional 15% of the shares of common stock offered in the public offering under the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Jefferies, TD Cowen, Leerink Partners and Stifel are acting as the joint book-running managers for the proposed offering. LifeSci Capital is acting as passive bookrunner for the proposed offering.

Spyre intends to use the net proceeds from the proposed public offering to continue to advance its programs in Gastroenterology, Rheumatology, and Dermatology, including to fund preclinical studies, clinical trials, manufacturing, and Phase 3 readiness, as well as a new program to advance SPY072 into late-stage development for hidradenitis suppurativa. Any remaining proceeds will be used for other ongoing research and development, working capital and other general corporate purposes.

A registration statement on Form S-3 (File No. 333-297063) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on June 26, 2026. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105, or by email at syndicate@leerink.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre’s pipeline includes investigational extended half-life antibodies targeting a4p7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

Safe Harbor / Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical fact are forward-looking statements. These forward-looking statements include statements regarding Spyre’s expectations regarding the proposed offering, including the timing, size, structure and completion of the proposed offering on the anticipated terms or at all and the satisfaction of customary closing conditions related to the offering. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect,” the negatives of these terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, the Company’s anticipated timing of the offering, market conditions and satisfaction of customary closing conditions related to the offering, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s ongoing or planned clinical trials for its product candidates; the Company’s ability to elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the previously disclosed data reported for the Company’s programs; the expected or potential impact of macroeconomic conditions, including inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in tariff/trade and monetary policy, volatile market conditions, financial institution instability, as well as geopolitical instability, including the ongoing military conflicts between the United States and Iran, Ukraine and Russia, conflicts in the Middle East, and geopolitical tensions between the United States and other countries, including China, on the Company’s operations; the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact the Company’s business operations, including restricting international trade by the United States, China or other countries; and those risks described in the Company’s most recent Annual Report on Form 10-K, its subsequent Quarterly Reports on Form 10-Q, as well as in other filings and reports that the Company makes from time to time with the SEC. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for the Company’s management to predict all risks, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. The Company undertakes no obligation to update publicly any forward-looking statement for any reason after the date of this press release to conform these statements to actual results, to reflect changes in the Company's expectations, or otherwise, except as required by law.

For Investors:
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com 

For Media:
Josie Butler, 1AB
josie@1abmedia.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What public offering has Spyre Therapeutics (SYRE) proposed?

Spyre has commenced an underwritten public offering of common stock. The company expects to give underwriters a 30-day option to purchase an additional 15% of the shares offered on the same terms and conditions. Completion remains subject to market and other conditions.

How does Spyre Therapeutics plan to use the offering proceeds?

Spyre intends to fund development of its Gastroenterology, Rheumatology and Dermatology programs, including preclinical studies, clinical trials, manufacturing and Phase 3 readiness. Planned funding also covers a new program to advance SPY072 into late-stage development for hidradenitis suppurativa. Remaining proceeds would support other ongoing research and development, working capital and general corporate purposes.